Cerebrolysin

Cerebrolysin is a porcine-derived neuropeptide mixture used off-label for cognitive support and neuroregeneration, with clinical research primarily focused on Alzheimer’s disease, stroke, and vascular dementia. Community users typically run daily doses ranging from 1 mg to 10 mg, though clinician-tier protocols utilize significantly higher daily intramuscular doses of 152 mg. Users frequently report changes in sleep patterns and vivid dreams, alongside occasional injection-site reactions. Readers should note that the evidence base for exploratory indications remains thin, as many trials lack posted results, making the current clinical support for off-label use more limited than common discourse suggests.

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.63.53.33.73.04.0

Research Evidence

Evidence shape

Cerebrolysin carries moderate clinical evidence, primarily supported by forty published human studies focused on neurological treatment. While the literature includes Phase 3 trials and twelve distinct sponsors, the breadth of research is fragmented, with twenty-nine mapped indications and only three trials providing blinded results. The vast majority of these indications remain exploratory or rely on single-trial data, signaling a significant gap between the volume of registered studies and the availability of robust, verified clinical outcomes.

Depthhow much
38 registered trials
18 completed · 3 with posted results · 7 recruiting / active · combined n=543
Breadthhow many areas
29 indications mapped
3 with results · 24 thin / exploratory · 1 animal-only · 18 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
3 blinded with results · 12 distinct sponsors · AE rows aggregated from 3 trials · 9 linked publications on registered trials
Breadth and depth92 rows captured
Human
direct clinical signal
78
Animal
translational support
12
In vitro
mechanistic support
2
HighMediumLow

Anecdotal efficacy

Cerebrolysin side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Progenixtech
--
1200 mg
$115.00
$0.1/mg
2
Mrbeetoe
--
360 mg
$73.00
$0.2/mg
3
Lucid Peptides
GB
60 mg
$23.83
$0.403/mg
4
Certapeptides
US
60 mg
$33.14
$0.549/mg
5
OP Labs
United Kingdom
60 mg
$33.42
$0.55/mg
6
Bionik Peptides
GB
60 mg
$33.56
$0.564/mg

price offers can be sorted by column

1-6 of 39

Cerebrolysin dosing & protocol

How Cerebrolysin is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 58
Typical dose
215.2 mg100 mg – 215.2 mg
typical
0
50 mg
100 mg
150 mg
200 mg
250 mg
distribution of 3 reported doses · darker = more
Frequency
weekly
Route
IM

In the research trials, Cerebrolysin was given intramuscularly at a typical dose of 215 mg once weekly, with individual doses ranging from 100 mg to 215 mg per week.

58 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
152 mg
typical
0
50 mg
100 mg
150 mg
200 mg
250 mg
single reported dose
Frequency
daily
Route
IM

Clinicians typically use a fixed dose of 152 mg cerebrolysin given by intramuscular injection each day, and no specific cycling schedule is described in the sources.

Anecdotal
Community-reported real-world use · n = 3
Typical dose
5 mg1 mg – 10 mg
typical
0
50 mg
100 mg
150 mg
200 mg
250 mg
distribution of 4 reported doses · darker = more
Frequency
unspecified
Route
IM

Community users most often take Cerebrolysin intramuscularly at about 5 mg, with reported doses spanning 1 mg to 10 mg; no specific frequency or cycling pattern emerged from the three reports.

3 sources

Related peptides

SelankSemaxDihexaNoopeptP21NSI-189AdamaxPE 22-28